Understanding clinical trials in COPD;Comprendre les essais cliniques dans la BPCO

Revue des Maladies Respiratoires

Volumn 22, Issue 4, 2005, Pages 561-565

  Calverley, P ^a  

^a UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUDESONIDE; CORTICOSTEROID; FLUTICASONE; TIOTROPIUM BROMIDE;

CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CORTICOSTEROID THERAPY; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; EDITORIAL; HUMAN; INFLAMMATION; LUNG EMPHYSEMA; MORTALITY; OXYGEN THERAPY; TREATMENT OUTCOME;

EID: 25844524115     PISSN: 07618425     EISSN: None     Source Type: Journal    
DOI: 10.1019/200530055     Document Type: Editorial

References (29)

1. Chronic obstructive pulmonary disease. National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care. Thorax 2004; 59 (Suppl 1): 1-232.
2. Pauwels RA, Buist AS, Calverley PMA, Jenkins CR, Hurd SS: Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 163: 1256-76.
3. Celli BR, MacNee W: Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23: 932-46.
4. Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L, Cherniack RM, Rogers RM, Sicurba FC, Coxson HO, Paré PD: The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004; 350: 2645-53.
5. Postma DS, Steenhuis EJ, van der Weele LT, Sluiter HJ: Severe chronic airflow obstruction: can corticosteroids slow down progression? Eur J Respir Dis 1985; 67: 56-64.
6. Brand PL, Quanjer PH, Postma DS, Kerstjens HA, Koeter GH, Dekhuijzen PN, Sluiter HJ: Interpretation of bronchodilator response in patients with obstructive airways disease. The dutch chronic non-specific lung disease (cnsld) study group. Thorax 1992; 47: 429-36.
7. Van Grunsven PM, Van Schayck CP, Derenne JP, Kerstjens HAM, Renkema TEJ, Postma DS, Similowski T, Akkermans RP, Pasker De Jong PCM, Dekhuijzen PNR, Van Herwaarden CLA, Van Weel C: Long term effects of inhaled corticosteroids in chronic obstructive pulmonary disease: A meta-analysis. Thorax 1999; 54: 7-14.
8. Calverley P, Pauwels R, Vestbo J, Jones P, Pride N, Gulsvik A, Anderson J, Maden C: Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: A randomised controlled trial. Lancet 2003; 361: 449-56.
9. Mahler DA, Wire P, Horstman D, Chang CN, Yates J, Fischer T, Shah T: Effectiveness of fluticasone propionate and salmeterol combination delivered via the diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002; 166: 1084-91.
10. Calverley PM, Burge PS, Spencer S, Anderson JA, Jones PW: Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax 2003; 58: 659-64.
11. Hansen EF, Phanareth K, Laursen LC, Kok-Jensen A, Dirksen A: Reversible and irreversible airflow obstruction as predictor of overall mortality in asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 159: 1267-71.
12. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA: Prednisolone response in patients with chronic obstructive pulmonary disease: results from the ISOLDE study. Thorax 2003; 58: 654-8.
13. Hospers JJ, Postma DS, Rijcken B, Weiss ST, Schouten JP: Histamine airway hyper-responsiveness and mortality in chronic obstructive pulmonary disease. Lancet 2000; 356: 1313-7.
14. Anthonisen NR, Connett JE, Kiley JP, Altose MD, Bailey WC, Buist AS, Conway WA, Jr., Enright PL, Kanner RE, O'hara P, et al.: Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of fev1. The lung health study. JAMA 1994; 272: 1497-505.
15. Anthonisen NR, Connett JE, Murray RP: Smoking and lung function of Lung Health Study participants after 11 years. Am J Respir Crit Care Med 2002; 166: 675-9.
16. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK: Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000; 320: 1297-303.
17. Calverley PM, Spencer S, Willits L, Burge PS, Jones PW: Withdrawal from treatment as an outcome in the ISOLDE study of COPD. Chest 2003; 124: 1350-6.
18. Calverley PM, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H: Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003; 22: 912-9.
19. Szafranski W, Cukier A, Ramirez A, Menga G, Sansores R, Nahabedian S, Peterson S, Olsson H: Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003; 21: 74-81.
20. Alsaeedi A, Sin DD, McAlister FA: The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trials. Am J Med 2002; 113: 59-65.
21. Sutherland ER, Allmers H, Ayas NT, Venn AJ, Martin RJ: Inhaled corticosteroids reduce the progression of airflow limitation in chronic obstructive pulmonary disease: a meta-analysis. Thorax 2003; 58: 937-41.
22. Jones PW, Willits LR, Burge PS, Calverley PM: Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease. Eur Respir J 2003; 21: 68-73.
23. Spencer S, Calverley PM, Burge PS, Jones PW: Impact of preventing exacerbations on deterioration of health status in COPD. Eur Respir J 2004; 23: 698-702.
24. Spencer S, Jones PW: Time course of recovery of health status following an infective exacerbation of chronic bronchitis. Thorax 2003; 58: 589-93.
25. van der V, Monninkhof E, van der PJ, Zielhuis G, van Herwaarden C: Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE study. Am J Respir Crit Care Med 2002; 166: 1358-63.
26. Juni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M: Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 2004; 364: 2021-9.
27. TORCH Study Group: The TORCH (towards a revolution in copd health) survival study protocol. Eur Respir J 2004; 24: 206-10.
28. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Report of the Medical Research Council Working Party. Lancet 1981; 1: 681-6.
29. Nocturnal Oxygen Therapy Trial Group: Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Ann Inter Med 1980; 93: 391-8.